# Artia Global Partners LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1937964. Source: https://holderbook.com/funds/1937964-artia-global-partners-lp/

- Reported value: $541.9M
- Positions: 48
- Weight of the ten largest: 64.5%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $68.8M | 516,447 | 12.7% | 4 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $62.8M | 589,052 | 11.6% | 11 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $41.2M | 2,210,852 | 7.6% | 5 |
| BRIGHTSPRING HEALTH SVCS INC | [BTSG](https://holderbook.com/stocks/BTSG/) | $36.1M | 517,315 | 6.7% | 4 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $34.7M | 185,390 | 6.4% | 8 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $27.6M | 29,739 | 5.1% | 15 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $23.5M | 448,964 | 4.3% | 1 |
| TRAVERE THERAPEUTICS INC | [TVTX](https://holderbook.com/stocks/TVTX/) | $19.3M | 339,033 | 3.6% | 6 |
| ASTRAZENECA PLC | [AZN](https://holderbook.com/stocks/AZN/) | $18.7M | 98,376 | 3.4% | 2 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMS](https://holderbook.com/stocks/NAMS/) | $17.1M | 503,936 | 3.2% | 5 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $15.9M | 162,990 | 2.9% | 4 |
| SPDR SERIES TRUST | [XBI](https://holderbook.com/stocks/XBI/) | $15.8M | 0 | 2.9% | 1 |
| QUEST DIAGNOSTICS INC | [DGX](https://holderbook.com/stocks/DGX/) | $13.8M | 65,122 | 2.5% | 6 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $11.4M | 144,376 | 2.1% | 4 |
| EYEPOINT INC | [EYPT](https://holderbook.com/stocks/EYPT/) | $11.0M | 767,098 | 2.0% | 11 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $7.8M | 278,546 | 1.4% | 2 |
| VIKING THERAPEUTICS INC | [VKTX](https://holderbook.com/stocks/VKTX/) | $7.1M | 180,731 | 1.3% | 15 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $6.2M | 59,316 | 1.1% | 3 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $6.0M | 70,700 | 1.1% | 2 |
| MERCK & CO INC | [MRK](https://holderbook.com/stocks/MRK/) | $6.0M | 46,700 | 1.1% | 2 |
| RAPPORT THERAPEUTICS INC | [RAPP](https://holderbook.com/stocks/RAPP/) | $5.8M | 138,508 | 1.1% | 4 |
| JOHNSON & JOHNSON | [JNJ](https://holderbook.com/stocks/JNJ/) | $5.7M | 22,600 | 1.1% | 2 |
| GUARDANT HEALTH INC | [GH](https://holderbook.com/stocks/GH/) | $5.7M | 38,100 | 1.1% | 1 |
| ABSCI CORPORATION | [ABSI](https://holderbook.com/stocks/ABSI/) | $5.4M | 464,444 | 1.0% | 1 |
| SCHOLAR ROCK HLDG CORP | [SRRK](https://holderbook.com/stocks/SRRK/) | $5.3M | 96,285 | 1.0% | 6 |
| SIONNA THERAPEUTICS INC | [SION](https://holderbook.com/stocks/SION/) | $5.3M | 119,741 | 1.0% | 3 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $4.7M | 17,740 | 0.9% | 1 |
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $4.6M | 129,800 | 0.8% | 3 |
| PALISADE BIO INC | [PALI](https://holderbook.com/stocks/PALI/) | $4.2M | 1,992,367 | 0.8% | 3 |
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $4.0M | 98,800 | 0.7% | 2 |
| BIOGEN INC | [BIIB](https://holderbook.com/stocks/BIIB/) | $4.0M | 18,437 | 0.7% | 2 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $3.9M | 65,000 | 0.7% | 10 |
| BELITE BIO INC | [BLTE](https://holderbook.com/stocks/BLTE/) | $3.8M | 24,989 | 0.7% | 3 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $3.7M | 137,800 | 0.7% | 5 |
| PROKIDNEY CORP | [PROK](https://holderbook.com/stocks/PROK/) | $3.7M | 1,806,939 | 0.7% | 3 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $3.7M | 72,100 | 0.7% | 2 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $3.2M | 33,400 | 0.6% | 1 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $2.8M | 22,951 | 0.5% | 13 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $2.7M | 5,000 | 0.5% | 6 |
| BRIGHT MINDS BIOSCIENCES INC | [DRUG](https://holderbook.com/stocks/DRUG/) | $2.7M | 38,407 | 0.5% | 3 |
| KINIKSA PHARMACEUTICALS INTL | [KNSA](https://holderbook.com/stocks/KNSA/) | $1.9M | 29,200 | 0.3% | 5 |
| COMPASS THERAPEUTICS INC | [CMPX](https://holderbook.com/stocks/CMPX/) | $839.2K | 383,200 | 0.2% | 1 |
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $837.0K | 2,500 | 0.2% | 3 |
| KODIAK SCIENCES INC | [KOD](https://holderbook.com/stocks/KOD/) | $663.1K | 17,019 | 0.1% | 3 |
| TENAX THERAPEUTICS INC | [TENX](https://holderbook.com/stocks/TENX/) | $612.3K | 42,080 | 0.1% | 3 |
| NUVALENT INC | [NUVL](https://holderbook.com/stocks/NUVL/) | $605.1K | 4,900 | 0.1% | 3 |
| PEPGEN INC | [PEPG](https://holderbook.com/stocks/PEPG/) | $369.6K | 205,324 | 0.1% | 3 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $355.1K | 4,000 | 0.1% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +8.9% | +14.8% | -5.9% | 89% |
| Q1 2026 | -8.0% | -4.6% | -3.4% | 84% |
| Q4 2025 | +7.9% | +2.4% | +5.6% | 84% |
| Q3 2025 | +20.1% | +7.8% | +12.3% | 96% |
| Q2 2025 | +7.8% | +10.5% | -2.6% | 86% |
| Q1 2025 | +3.2% | -4.6% | +7.7% | 92% |
| Q4 2024 | -16.4% | +2.1% | -18.6% | 96% |
| Q3 2024 | -1.7% | +5.4% | -7.1% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $541.9M | 48 |
| Q1 2026 | $499.4M | 49 |
| Q4 2025 | $705.8M | 50 |
| Q3 2025 | $630.9M | 48 |
| Q2 2025 | $415.6M | 35 |
| Q1 2025 | $395.1M | 32 |
| Q4 2024 | $279.8M | 35 |
| Q3 2024 | $366.9M | 44 |
| Q2 2024 | $517.3M | 46 |
| Q1 2024 | $497.5M | 49 |
| Q4 2023 | $343.7M | 31 |
| Q3 2023 | $240.6M | 27 |